Logo

Healx Collaborated with Ovid to Develop and Commercialize Gaboxadol for Fragile X Syndrome

Share this

Healx Collaborated with Ovid to Develop and Commercialize Gaboxadol for Fragile X Syndrome

Shots:

  • Ovid to receive milestones payments upon achievement of clinical, regulatory & commercial milestones for gaboxadol’s development along with royalties on net sales based on marketed therapies containing gaboxadol
  • The recent collaboration follows Healx’s Aug 2021 research collaboration agreement with Ono. Healx obtains exclusive license rights to develop & commercialize gaboxadol while Ovid gets an option to become Healx’s co-development & co-commercialization partner and will share net profits & losses
  • Healx plans to explore gaboxadol in combination therapies for Fragile X syndrome & for other indications & plans to utilize its cutting-edge indication expansion technology to identify other conditions

Ref: Globe Newswire | Image: Businesswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions